Abstract
Purpose
Pre-clinical and early clinical data suggests the microbiome plays an important role in oncogenesis and influences response to immune checkpoint blockade (ICB). The objective of this systematic review and meta-analysis was to determine whether antibiotics affect overall survival (OS) and progression free survival (PFS) in patients with solid malignancies treated with ICB.
Patients and methods
A systematic search of EMBASE, MEDLINE and conference proceedings was conducted for observational studies examining the effect of antibiotics on ICB. A random effects study-level meta-analysis was performed with pooling of the hazards ratio (HR) for OS and PFS. Meta-regression was used to determine the impact of the timing of antibiotic exposure on OS.
Results
766 studies were identified, and 18 studies met the inclusion criteria. Of the 2889 patients included, 826 (28.6%) were exposed to antibiotics. The most common malignancies were lung (59%), renal cell carcinoma (RCC) or urothelial carcinoma (16.3%) and melanoma (18.7%). OS was prolonged in those without antibiotic exposure (pooled HR 1.92, 95% CI 1.37–2.68, p < 0.001). The effect of antibiotics on OS was greater in studies defining antibiotic exposure as 42 days prior to initiation of ICB (HR 3.43, 95% CI 2.29–5.14, p < 0.0001). PFS was also longer in patients who did not receive antibiotics (pooled HR 1.65, 95% CI 1.3–2.1, p < 0.0001).
Conclusion
In patients receiving ICB, OS and PFS are longer in patients who are not exposed to antibiotics. Antibiotic use in the 42 days before starting ICB appears to be most detrimental to outcome.
Similar content being viewed by others
Abbreviations
- CAR-T:
-
Chimeric antigen receptor T cell
- CTLA-4:
-
Cytotoxic T lymphocyte associated protein 4
- ECOG:
-
Eastern Co-operative Oncology Group
- HR:
-
Hazard ratio
- ICB:
-
Immune checkpoint blockade
- NSCLC:
-
Non-small cell lung cancer
- OS:
-
Overall survival
- PD-1:
-
Programmed cell death protein—1
- PD-L1:
-
Programmed death—ligand 1
- PFS:
-
Progression free survival
- RCC:
-
Renal cell carcinoma
References
Vétizou M, Pitt JM, Daillère R, Lepage P, Waldschmitt N, Flament C, Rusakiewicz S, Routy B, Roberti MP, Duong CP (2015) Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350(6264):1079–1084
Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, Benyamin FW, Lei YM, Jabri B, Alegre M-L (2015) Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy. Science 350(6264):1084–1089
Gopalakrishnan V, Spencer C, Nezi L, Reuben A, Andrews M, Karpinets T, Prieto P, Vicente D, Hoffman K, Wei S (2018) Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients. Science 359(6371):97–103
Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, Boselli L, Routier E, Cassard L, Collins M (2017) Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol 28(6):1368–1379
Huemer F, Rinnerthaler G, Lang D, Hackl H, Lamprecht B, Greil R (2019) Association between antibiotics use and outcome in patients with NSCLC treated with immunotherapeutics. Ann Oncol 30(4):652–653
Ahmed J, Kumar A, Parikh K, Anwar A, Knoll BM, Puccio C, Chun H, Fanucchi M, Lim SH (2018) Use of broad-spectrum antibiotics impacts outcome in patients treated with immune checkpoint inhibitors. OncoImmunology 7(11):e1507670
Derosa L, Hellmann M, Spaziano M, Halpenny D, Fidelle M, Rizvi H, Long N, Plodkowski A, Arbour K, Chaft J (2018) Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann Oncol 29(6):1437–1444
Elkrief A, El Raichani L, Richard C, Messaoudene M, Belkaid W, Malo J, Belanger K, Miller W, Jamal R, Letarte N (2019) Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors. OncoImmunology 8:1–6
Kaderbhai C, Richard C, Fumet JD, Aarnink A, Foucher P, Coudert B, Favier L, Lagrange A, Limagne E, Boidot R (2017) Antibiotic use does not appear to influence response to Nivolumab. Anticancer Res 37(6):3195–3200
Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8(1):16
Weinstock CMV, Fernandes LL, Tang S, Agrawal S, Brave MH, Ning YM, Singh H, Suzman DL, Xu J, Goldberg KB, Srihara R, Ibrahim A, Theoret MR, Beaver JA, Pazdur R (2019) Impact of antibiotic use on clinical outcomes in patents with urothelial cancer receiving a programmed death protein 1 or programmed death ligant (and-PD1/L1) antibody. J Clin Oncol 37:4557
Chalabi M, Cardona A, Nagarkar D, Scala AD, Albert M, Kok M, Powles T, Herrera F (2018) Effects of antibiotics and proton pump inhibitors in NSCLC patients treated with atezolizumab and docetaxel: pooled analysis of the OAK and POPLAR trials. Ann Oncol 29(supplemental 10):486.001
Routy B, Le Chatelier E, Derosa L, Duong CP, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP (2018) Gut microbiome influences efficacy of PD-1—based immunotherapy against epithelial tumors. Science 359(6371):91–97
Huemer F, Rinnerthaler G, Westphal T, Hackl H, Hutarew G, Gampenrieder SP, Weiss L, Greil R (2018) Impact of antibiotic treatment on immune-checkpoint blockade efficacy in advanced non-squamous non-small cell lung cancer. Oncotarget 9(23):16512–16520
Kulkarni AKM, Pease DF, Want Y, deFor TE, Patel M (2019) Impact of antibiotics and proton pump inhibitors on clinical outcomes of immune check point blockers in advanced non-small cell lung cancers and metastatic renal cell cancers. J Clin Oncol 37:e20520
Pinato DJHS, Ottaviani D, Urus H, Patel A et al (2019) Antibiotic treatment prior to immune checkpoint inhibitor therapy as a tumor-agnostic predictive correlate of response in routine clinical practice. J Clin Oncol 37(supplemental 8):147
Do TP, Hegde AM, Cherry CR, Stroud CRG, Sharma N, Cherukuri SD, Bowling M, Walker PR (2019) Antibiotic use and overall survival in lung cancer patients receiving nivolumab. J Clin Oncol 36(supplement 15):e15109
Masini CBA, Romagnani A, Bonelli C, Fantinel E, Pagano M, Banzi M, Prati G, Gasparini E, Moretti G, Gervasi E, Gnoni R, Stridi G, Pinto C (2019) Results of an Italian CORE-IMMUNO study: safety and clinical-related biomarkers as predictors of immunotherapy (IT) benefit in real-world treatment of various advanced tumors (ATs). J Clin Oncol 37:e14156
Sen S, Carmagnani Pestana R, Hess K, Viola G, Subbiah V (2018) Impact of antibiotic use on survival in patients with advanced cancers treated on immune checkpoint inhibitor phase I clinical trials. Ann Oncol 29(12):2396–2398
Mielgo-Rubio X, Chara L, Sotelo-Lezama M, Castro RL, Rubio-Martínez J, Velastegui A, Olier-Garate C, Falagan S, Gómez-Barreda I, Bautista-Sanz P (2018) Antibiotic use and PD-1 inhibitors: shorter survival in lung cancer, especially when given intravenously. Type of infection also matters. J Thorac Oncol 13(10):S389
Hemadri ALH, Lin Y, Rose A, Sander C, Najjar Y, Zarour HM, Kirkwood JM, Davar D (2019) Association of medication and antibiotic use with response and survival in advanced melanoma receiving PD-1 inhibtors. J Clin Oncol 37(supplemental 15):9572
Thompson J, Szabo A, Arce-Lara C, Menon S (2017) Microbiome and immunotherapy: antibiotic use is associated with inferior survival for lung cancer patients receiving PD-1 inhibitors. J Thorac Oncol 12(11)(supplement 2):S1998
Zhao S, Gao G, Li W, Li X, Zhao C, Jiang T, Jia Y, He Y, Li A, Su C (2019) Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer. Lung Cancer 130:10–17
Schett ARS, Mauti LA, Schmid S, Appenzeller C, Curioni-Fontecedro A, Frueh M, Joerger M (2019) Progsnotic impact of the use of antibiotics in patients with advanced non-small cell lung cancer receiving PD-(L)1 targeting monoclonal antibodies. Ann Oncol 30(Supplemental 2):157
Tinsley N, Zhou C, Tan G, Rack S, Lorigan P, Blackhall F, Krebs M, Carter L, Thistlethwaite F, Graham D (2019) Cumulative Antibiotic Use Significantly Decreases Efficacy of Checkpoint Inhibitors in Patients with Advanced Cancer. Oncologist 24:1–9
Lalani A-KA, Xie W, Lin X, Steinharter JA, Martini DJ, Duquette A, Bosse D, McKay RR, Simantov R, Wei XX (2018) Antibiotic use and outcomes with systemic therapy in metastatic renal cell carcinoma (mRCC). J Clin Oncol 36(supplemental 6):607
Pinato DJ, Howlett S, Ottaviani D, Urus H, Patel A, Mineo T, Brock C, Power D, Hatcher O, Falconer A (2019) Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer. JAMA Oncol 5(12):1774–1778
Palleja A, Mikkelsen KH, Forslund SK, Kashani A, Allin KH, Nielsen T, Hansen TH, Liang S, Feng Q, Zhang C et al (2018) Recovery of gut microbiota of healthy adults following antibiotic exposure. Nat Microbiol 3(11):1255–1265
Dethlefsen L, Huse S, Sogin ML, Relman DA (2008) The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol 6(11):e280
Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre M-L, Luke JJ, Gajewski TF (2018) The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients. Science 359(6371):104–108
Frankel AE, Coughlin LA, Kim J, Froehlich TW, Xie Y, Frenkel EP, Koh AY (2017) Metagenomic shotgun sequencing and unbiased metabolomic profiling identify specific human gut microbiota and metabolites associated with immune checkpoint therapy efficacy in melanoma patients. Neoplasia 19(10):848–855
Geva-Zatorsky N, Sefik E, Kua L, Pasman L, Tan TG, Ortiz-Lopez A, Yanortsang TB, Yang L, Jupp R, Mathis D (2017) Mining the human gut microbiota for immunomodulatory organisms. Cell 168(5):928–943
Depommier C, Everard A, Druart C, Plovier H, Van Hul M, Vieira-Silva S, Falony G, Raes J, Maiter D, Delzenne NM (2019) Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat Med 25(7):1096
Krief JO, de Tauriers PH, Dumenil C, Neveux N, Dumoulin J, Giraud V, Labrune S, Tisserand J, Julie C, Emile J-F (2019) Role of antibiotic use, plasma citrulline and blood microbiome in advanced non-small cell lung cancer patients treated with nivolumab. J Immunother Cancer 7(1):176
van Vliet MJ, Tissing WJ, Rings EH, Koetse HA, Stellaard F, Kamps WA, de Bont ES (2009) Citrulline as a marker for chemotherapy induced mucosal barrier injury in pediatric patients. Pediatr Blood Cancer 53(7):1188–1194
Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, Von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389(10066):255–265
Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, Park K, Smith D, Artal-Cortes A, Lewanski C (2016) Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 387(10030):1837–1846
Tinsley NZC, Villa SS, Tan G, Lorigan P, Blackhall FH, Elliott T, Krebs M, Carter L, Thistlethwaite F, Hughes A, Cook N (2018) Cumulative antibiotic use and efficacy of immune checkpoint inhibitors in patients with advanced cancer. J Clin Oncol 36(supplemental 15):3010
Galli G, Poggi M, Fuca G, Imbimbo M, Proto C, Signorelli D, Vitali M, Zilembo N, Ganzinelli M, De Braud F et al (2018) Impact of antibiotics on outcome of metastatic non small cell lung cancer patients treated with immunotherapy. J Thorac Oncol 13(Supplement 10):S389
Rossi G, Pezzuto A, Sini C, Tuzi A, Citarella F, McCusker MG, Nigro O, Tanda E, Russo A (2019) Concomitant medications during immune checkpoint blockage in cancer patients: novel insights in this emerging clinical scenario. Crit Rev Oncol Hematol 142:26–34
Hakozaki T, Okuma Y, Omori M, Hosomi Y (2019) Impact of prior antibiotic use on the efficacy of nivolumab for non-small cell lung cancer. Oncol Lett 17(3):2946–2952
Lalani AKA (2019) Effect of antibiotic use on outcomes with systemic therapies in metastatic renal cell carcinoma. In. Personal communication regarding unpublished data
Khan U, Peña C, Brouwer J, Hoffman K, Choudhury AR, Zhang C, Thakkar P, Betel D, Sarkar S, Sonnenberg G (2019) Impact of antibiotic use on response to treatment with immune checkpoint inhibitors. J Clin Oncol 37(supplemental 4):143
Agarwal A, Pond GR, Curran C, Nassar A, Nuzzo PV, Kumar V, McGregor BA, Wei XX, Harshman LC, Choueiri TK et al (2019) Impact of concurrent medications on outcomes with PD1/PDL1 inhibitors for metastatic urothelial carcinoma. J Clin Oncol 37(Supplement 7):435
Metges J-P, Michaud E, Deniel Lagadec D, Marhuenda F, Chaslerie A, Grude F (2018) Impact of anti-infectious and corticosteroids on immunotherapy: Nivolumab and pembrozilumab follow-up in a French study. J Clin Oncol 36 (supplemental 15):e15157
Spakowicz DHM, Tinoco G, Patel SH, Murkart JT, Verscharegen SF, Ekndra KL, Hoffman S, Philippon J, Quiroga DM, Otterson GA, Owen DH (2019) Effect of concomittant medications on overall survival in patients with cancer undergoing immunotherapy. J Clin Oncol 37(supplemental 8):94
Wang YWD, Helmink BA, Gopalakrishnan V, Choi K, Dupont HL et al (2018) Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Rev 24(12):1804–1808
Kapoor VRJ, Boyce T, Pankratz VS, Rixe O (2019) Effect of antibiotic exposure in patients with metastatic melanoma treated with PD-1 inhibitor or CTLA-4 inhibitor or a combination of both. J Clin Oncol 37 (supplemental 15):e14141
Derosa L, Routy B, Enot D, Baciarello G, Massard C, Loriot Y, Fizazi K, Escudier BJ, Zitvogel L, Albiges L (2017) Impact of antibiotics on outcome in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors. J Clin Oncol 35(6 Supplement 1):462
Derosa L, Routy B, Enot D, Fidelle M, Gubet AG, Goldwasser F, Zitvogel L, Loriot Y, Albiges L, Escudier B (2018) Impact of antibiotics on outcome in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors. Kidney Cancer 2(Supplement 1):S24–S25
Derosa L, Routy B, Mezquita L, Naltet C, Enot D, Fidelle M, Goubet AG, Soria JC, Massard C, Goldwasser F et al (2017) Antibiotics prescription to decrease progression-free survival (PFS) and overall survival (OS) in patients with advanced cancers treated with PD1/PDL1 immune checkpoint inhibitors. J Clin Oncol 35(15 Supplement 1):3015
Zhao S, Jia Y, Jiang T, Li X, Li W, Gao G, Zhao C, He Y, Chen X, Su C et al (2018) Antibiotics attenuate the clinical benefit of anti-PD-(L)1 immunotherapies in Chinese patients with advanced non-small cell lung cancer. J Thorac Oncol 13(10 Supplement):S930
Wilson BE, Routy B, Nagrial A, Chin V (2019) The effect of antibiotics on clinical outcomes in immune-checkpoint blockade: a systematic review and meta-analysis of observational studies. Asia-Pacific J Clin Oncol 15(supplemental 9):359
Funding
No relevant funding.
Author information
Authors and Affiliations
Contributions
BEW: project design, data extraction, data analysis, manuscript writing. BR: manuscript revision and advice. AN: manuscript revision and advice. VC: project design, data extraction, data interpretation and manuscript revision
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
As this study was based on published data, no ethics approval was sought for the study.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Wilson, B.E., Routy, B., Nagrial, A. et al. The effect of antibiotics on clinical outcomes in immune-checkpoint blockade: a systematic review and meta-analysis of observational studies. Cancer Immunol Immunother 69, 343–354 (2020). https://doi.org/10.1007/s00262-019-02453-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00262-019-02453-2